DONEPEZIL.
DONE WEEKLY.
DONE FOR THEM.
Introducing ADLARITY®, the first and only
once-weekly donepezil transdermal system
IMPROVING THE TREATMENT EXPERIENCE
Reimagine the most trusted medicine for Alzheimer's dementia
The oral form of donepezil has been the mainstay of treatment for people with Alzheimer's dementia since its introduction in 1996. Nonetheless, there is room for improvement.
Alzheimer's disease is marked by memory loss in people who often have other health problems. Compliance, pill burden, and gastrointestinal (GI) adverse events with donepezil can be challenges for patients and caregivers alike.
Donepezil, done right
The heart of ADLARITY is the technology that makes it possible. Innovative, patented CorplexTM technology transforms donepezil into a once-weekly transdermal system. One patch replaces 7 days of oral therapy, and drug absorption bypasses the GI tract.
An innovative technology must be brought to life through an equally innovative campaign. Advanced 3-D design and animations showcase how ADLARITY offers a groundbreaking way to experience donepezil treatment.
